Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic ...
Feb 13 (Reuters) - Softbank-backed (9434.T), opens new tab genetic test maker Invitae (NVTA.PK), opens new tab said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy ...
Invitae boosted its genetic testing menu with a new test for the diagnosis of spinal muscular atrophy, the second-leading genetic disease in infants. The test provides “significant improvements” over ...
San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...
Feb 5 (Reuters) - Genetic test maker Invitae (NVTA.N), opens new tab is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results